Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC. RATIONALE: Nasal polyp tissue contributes to the burden of aspirin exacerbated respiratory disease (AERD) by altering eicosanoid patterns.AERDis diagnosed through graded aspirin challenges. It is not well understood whether polypectomy/sinus surgery affects aspirin challenge outcomes. We investigated the effect of endoscopic sinus surgery (ESS) on aspirin-induced reactions and on the levels of eicosanoids, which are associated with aspirin-induced reactions in AERD. METHODS: Twenty-eight AERD patients were challenged with aspirin before and 3-4 weeks after ESS. Respiratory parameters and plasma and urine levels of eicosanoids were compared before and after each challenge. RESULTS: Before ESS, AERD diagnosis was confirmed in all study patients by aspirin challenges that resulted in clinically apparent hypersensitivity reactions. After ESS, reactions to aspirin were less severe in all patients and twelve out of twenty-eight patients (43%, p<0.001)had no clinically obvious reaction. Lack of clinical reaction to aspirin was associated with lower peripheral blood eosinophilia [0.1 cells/mL (IQR 0.1-0.3) vs. 0.4 cells/mL (IQR 0.2-0.8) in those who reacted, p50.006], lower urinary leukotriene E 4 (LTE 4 ) levels after aspirin challenge [98 pg/mg creatinine (IQR 61-239) vs. 459 pg/mg creatinine (IQR 141-1344) in those who reacted to aspirin, p50.02], and lower plasma prostaglandin D 2 to prostaglandin E 2 (PGD 2 /PGE 2 ) ratio [0 (60) vs. 0.43 (60.2) in those who reacted, p50.03]. CONCLUSIONS: Nasal polyp removal results in decreased aspirin sensitivity and a decrease in the production of eicosanoids related to aspirin-induced reactions in AERD. Aspirin challenges should be offered to appropriate patients prior to ESS to increase diagnostic accuracy.
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The Xolair Pregnancy Registry (EXPECT): Perinatal outcomes among pregnant women with asthma treated with omalizumab (Xolair) compared against those of a cohort of pregnant women with moderate-to-severe asthma Novartis, Inc., East Hanover, NJ. RATIONALE: The EXPECT pregnancy registry was a prospective observational study established in 2006 to evaluate perinatal outcomes in women exposed to omalizumab during pregnancy. Because asthma in pregnant women itself is associated with adverse perinatal outcomes, the final EXPECT results were compared against a cohort of pregnant women with moderate-to-severe asthma unexposed to omalizumab. METHODS: 250 women exposed to omalizumab during their pregnancy were enrolled in EXPECT, and perinatal outcomes were collected up to 18 months after delivery. The disease-matched external comparator cohort of pregnant women not exposed to omalizumab (n51,153), the Quebec External Comparator Cohort (QECC), was created using data from healthcare databases, and outcome estimates were age-adjusted to the age distribution of the EXPECT cohort. RESULTS: Among singleton infants in EXPECT, the prevalence of major congenital anomalies was 8.1% (18/223), similar to that in QECC (8.9%). In EXPECT, 99.1% of pregnancies led to a live birth and 0.9% ended in at least one fetal death/stillbirth, similar to the 99.3% and 0.9%, respectively, found in QECC. Premature birth and small for gestational age (SGA) were identified in 15.0% and 9.7% of EXPECT infants, respectively, and 11.3% and 15.8%, respectively, in QECC. CONCLUSIONS: Although this study cannot definitively establish the absence of any increased risk with omalizumab, there was no evidence of an increased risk of major congenital anomalies following exposure to omalizumab among pregnant women compared to a disease-matched cohort of pregnant women with moderate-to-severe asthma. RATIONALE: Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated by large-scale doubleblinded placebo control studies. However, a prospective open-label study of a long-term subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma has not been reported. METHODS: This study was a prospective, 48-week, open-label trial in 32 Japanese patients with severe eosinophilic asthma who received subcutaneous administration of 100 mg mepolizumab every 4 weeks. Nine patients required daily use of oral corticosteroid despite the use of highdose inhaled corticosteroid. Six patients with aspirin-exacerbated respiratory disease were involved. RESULTS: No patients failed to be continued mepolizumab administration for an entire trial period. All patients experienced no adverse events during the treatment. None of the patients experienced asthma exacerbations during an entire period. In fact, forced expiratory volume in one second was increased significantly at 24 week (p < 0.01) and at 48 week (p < 0.05). Number of eosinophils in peripheral blood was reduced after the first administration of mepolizumab in all patients, which was continued until 48 weeks with mepolizumab administration. After the start of mepolizumab administration, all of oral corticosteroid-dependent asthmatics successfully withdrew from the use of corticosteroid without exacerbations in parallel with sustained reduction in peripheral blood eosinophil count. Blood levels of thymus and activation-regulated chemokine and IgE were not changed with 48-week administration of mepolizumab.
CONCLUSIONS:
This first prospective open-label pilot study in Japan showed a long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma.
